Financial Highlights - Catheter Precision reported total assets of 11.8 million as of December 31, 2024 [3] - The company had 8,004,633 outstanding shares of common stock by the end of 2024 [3] - Fourth quarter revenue reached 420 thousand [3] - The net loss for the fourth quarter was 3.1 million attributed to non-cash charges; total net loss for 2024 was 7.5 million in non-cash charges [3] Operational Updates - A new Chief Commercial Officer joined in Q2 2024, leading to a significant overhaul of the sales team [3] - The first sales of the LockeT device occurred in Q2 2024, with sales growing sequentially each quarter [3] - By year-end 2024, 26 hospitals had evaluated the LockeT device through surgical procedures [3] - The company completed audits for LockeT's CE Mark in Q4 2024, with expectations to receive the CE Mark in Q2 2025, allowing sales in 32 European countries starting Q3 2025 [3] - VIVO marketing and sales efforts are ongoing in the US and several international markets, including Germany, Turkey, and the UK [3] Clinical Studies and Publications - Two clinical studies were published in 2024, focusing on non-invasive mapping systems and the combination of cardiac imaging with electrocardiographic information [3] - The first LockeT journal manuscript and two abstracts were published in 2024, detailing the feasibility, safety, and efficacy of the LockeT device [3] - Additional clinical studies for both VIVO and LockeT are ongoing or planned for 2025, including a Randomized Controlled Trial (RCT) for VIVO set to begin in Q3 2025 [3]
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results